Reolysin: Preliminary Phase I data

Preliminary data from the single-arm, open-label, dose-escalation, U.S. Phase I REO 022 trial in 18 evaluable patients with oxaliplatin-refractory mutant KRAS mCRC showed that IV Reolysin on days 1-5 ...